Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36–44]

European Journal of Cancer ◽

10.1016/j.ejca.2017.05.003 ◽

2017 ◽

Vol 81 ◽

pp. 242 ◽

Cited By ~ 2

Author(s):

Christophe Massard ◽

Kim Nguyen Chi ◽

Daniel Castellano ◽

Johann de Bono ◽

Gwenaelle Gravis ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Phase Ib ◽

Castration Resistant ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2017.01.024 ◽

2017 ◽

Vol 76 ◽

pp. 36-44 ◽

Cited By ~ 29

Author(s):

Christophe Massard ◽

Kim Nguyen Chi ◽

Daniel Castellano ◽

Johann de Bono ◽

Gwenaelle Gravis ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Phase Ib ◽

Castration Resistant ◽

Finding Study ◽

Dose Finding Study

Download Full-text

A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1115 ◽

2021 ◽

pp. clincanres.1115.2021

Author(s):

Debashis Sarker ◽

Nancy A. Dawson ◽

Ana M. Aparicio ◽

Tanya B Dorff ◽

Allan J. Pantuck ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Castration Resistant ◽

Finding Study ◽

Label Dose ◽

Dose Finding Study

Download Full-text

Phase I, open-label, dose-finding study of GSK2636771, a phosphoinositide 3-kinase (PI3K)β inhibitor, in combination with enzalutamide in male subjects with metastatic castration-resistant prostate cancer (mCRPC)

Annals of Oncology ◽

10.1093/annonc/mdx370.009 ◽

2017 ◽

Vol 28 ◽

pp. v273 ◽

Cited By ~ 1

Author(s):

P. Rescigno ◽

J. de Bono ◽

A. Aparicio ◽

S. Chowdhury ◽

P. Twardowski ◽

...

Keyword(s):

Prostate Cancer ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Open Label ◽

Castration Resistant ◽

Finding Study ◽

Label Dose ◽

Dose Finding Study ◽

Phosphoinositide 3 Kinase ◽

Male Subjects

Download Full-text

Abstract A90: Efficacy and tolerability of cabozantinib at lower dose: A dose finding study in men with castration-resistant prostate cancer and bone metastases.

10.1158/1535-7163.targ-11-a90 ◽

2011 ◽

Cited By ~ 1

Author(s):

Richard J.B. Lee ◽

M. Dror Michaelson ◽

Philip Saylor ◽

Carol Gurski ◽

Jonathan G. Goldin ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.5027 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 5027-5027 ◽

Cited By ~ 9

Author(s):

Christopher Sweeney ◽

Kathryn P. Gray ◽

Lauren Christine Harshman ◽

Aymen Elfiky ◽

Toni K. Choueiri ◽

...

Keyword(s):

Prostate Cancer ◽

Combination Therapy ◽

Phase 1 ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Finding Study ◽

Dose Finding Study

Download Full-text

2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC)

European Journal of Cancer ◽

10.1016/s0959-8049(16)31369-7 ◽

2015 ◽

Vol 51 ◽

pp. S493

Author(s):

K. Chi ◽

D. Castellano ◽

J. De Bono ◽

G. Gravis ◽

L. Dirix ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase Ib ◽

Castration Resistant

Download Full-text

A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer

The Prostate ◽

10.1002/pros.23662 ◽

2018 ◽

Vol 78 (14) ◽

pp. 1053-1062 ◽

Cited By ~ 3

Author(s):

Atish D. Choudhury ◽

Kathryn P. Gray ◽

Jeffrey G. Supko ◽

Lauren C. Harshman ◽

Mary-Ellen Taplin ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trial ◽

Abiraterone Acetate ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text

Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-19-3402 ◽

2020 ◽

Vol 26 (14) ◽

pp. 3517-3524

Author(s):

Edwin M. Posadas ◽

Kim N. Chi ◽

Ronald de Wit ◽

Maja J.A. de Jonge ◽

Gerhardt Attard ◽

...

Keyword(s):

Prostate Cancer ◽

Antitumor Effect ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Phase Ib ◽

Castration Resistant

Download Full-text

7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71402-8 ◽

2009 ◽

Vol 7 (2) ◽

pp. 413-414 ◽

Cited By ~ 2

Author(s):

U. Vaishampayan ◽

D. Rathkopf ◽

K.N. Chi ◽

S. Hotte ◽

N. Vogelzang ◽

...

Keyword(s):

Prostate Cancer ◽

Dose Finding ◽

Castration Resistant Prostate Cancer ◽

Phase Ib ◽

Castration Resistant

Download Full-text

18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate

Case Medical Research ◽

10.31525/ct1-nct04158245 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant

Download Full-text